folic acid
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | FOLVRON | — | 1946-08-13 | fda.gov ↗ |
Trials 100 · started per year
Also used as a comparator or background therapy in 117 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04989049 Comparator | Sep → Nov 2022 | ulcerative stomatitis | Dow University of Health Sciences | Unknown | No outcome recorded |
| Phase 19 trials | ||||||
| Phase 1 | NCT03766594 Comparator | Jan → Nov 2018 | pregnancy loss, recurrent, 4 | Ain Shams University | Completed | No outcome recorded |
| Phase 1 | NCT03242993 Background | Apr 2017 → Jun 2019 | lung cancer, ovarian cancer | University of Lausanne Hospitals | Completed | No outcome recorded |
| Phase 1 | NCT03101579 Background | Mar 2017 → Sep 2018 | malignant tumor of meninges | The First Hospital of Jilin University | Completed | No outcome recorded |
| Phase 1 | NCT02699710 Background | Sep 2015 → May 2016 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01873443 Background | May 2013 → Oct 2014 | rheumatoid arthritis | Celltrion | Completed | No outcome recorded |
| Phase 1 | NCT01850680 Background | Apr → Dec 2013 | rheumatoid arthritis | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT00452829 Background | Sep 2009 → Jun 2013 | neural tube defect | Institute of Child Health | Completed | No outcome recorded |
| Phase 1 | NCT00965653 Background | Aug 2009 → Jul 2011 | rheumatoid arthritis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT00034463 Background | — | cancer, metastatic neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT07284277 Background | Oct 2025 → Mar 2027 expected | pancreatic ductal adenocarcinoma | Clinica Universidad de Navarra, Universidad de Navarra | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05289908 Background | Feb 2022 → Mar 2023 | malignant leptomeningeal tumor | The First Hospital of Jilin University | Completed | No outcome recorded |
| Phase 1/2 | NCT03823248 Comparator | Mar 2019 → Dec 2021 | preneoplastic lesion | Xiyuan Hospital of China Academy of Chinese Medical Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT03028467 Background | Jan → Dec 2017 | rheumatoid arthritis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/2 | NCT01704794 Comparator | Apr 2013 → Apr 2014 | sickle cell disease | Lagos State University | Unknown | No outcome recorded |
| Phase 1/2 | NCT01703104 Comparator | Jan → Mar 2012 | sickle cell disease | Lagos State University | Completed | No outcome recorded |
| Phase 1/2 | NCT01188876 Background | Aug 2010 → Jul 2016 | fallopian tube cancer, ovarian cancer, peritoneum cancer | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 231 trials | ||||||
| Phase 2 | NCT06855849 Background | May 2025 → May 2027 expected | colorectal cancer | Yonsei University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06768294 Background | Jan 2025 → Jun 2026 overdue | chondrocalcinosis | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06459921 Comparator | Dec 2024 → Jul 2026 overdue | gastric cancer | Xijing Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07292259 Background | Jan 2024 → Dec 2025 | beta-thalassemia major | Pakistan Blood and Marrow Transplant (PBMT) Group | Completed | No outcome recorded |
| Phase 2 | NCT05959044 Comparator | Apr 2023 → Jul 2024 | Parkinson disease | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Unknown | No outcome recorded |
| Phase 2 | NCT05616000 Background | Aug → Nov 2022 | male infertility | Khyber Medical University Peshawar | Completed | No outcome recorded |
| Phase 2 | NCT05363917 Background | Jun → Dec 2022 | rheumatoid arthritis | XBiotech, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT03977272 Comparator | Mar 2019 → Jul 2022 | malignant pancreatic neoplasm | Zhejiang University | Completed | No outcome recorded |
| Phase 2 | NCT02795299 Comparator | Jan 2018 → May 2019 | rheumatoid arthritis | Bird Rock Bio, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT03581773 Comparator | Dec 2017 → Sep 2026 expected | stomatitis | Niels Fristrup | Recruiting | No outcome recorded |
| Phase 2 | NCT02833350 Background | Sep 2016 → Jul 2018 | rheumatoid arthritis | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02504671 Background | Jul 2015 → Dec 2017 | rheumatoid arthritis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02467504 Comparator | Jul 2015 → Jan 2017 | rheumatoid arthritis | Peking University People's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT05378919 Comparator | Jun 2015 → Jun 2025 overdue | — | Lithuanian University of Health Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT02393378 Background | Apr 2015 → Jun 2016 | rheumatoid arthritis | Takeda | Terminated | No outcome recorded |
| Phase 2 | NCT02106650 Background | Jul 2014 → Oct 2018 | peripheral T-cell lymphoma, not otherwise specified | Acrotech Biopharma Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01953536 Background | Apr 2014 → Nov 2016 | breast neoplasm | Endocyte | Withdrawn | No outcome recorded |
| Phase 2 | NCT02079948 Background | Feb → Sep 2014 | — | University of Florida | Withdrawn | No outcome recorded |
| Phase 2 | NCT01670955 Comparator | Dec 2012 → Jun 2013 | anemia | Lagos State University | Completed | No outcome recorded |
| Phase 2 | NCT01490944 Background | Jan → Nov 2012 | anemia | Indian Council of Medical Research | Unknown | No outcome recorded |
| Phase 2 | NCT01384994 Comparator | Aug 2011 → Aug 2013 | colorectal cancer | PD Dr. med. Volker Heinemann | Unknown | No outcome recorded |
| Phase 2 | NCT04154852 Background | Jun 2011 → Jan 2017 | arthritic joint disease | University of Leeds | Completed | No outcome recorded |
| Phase 2 | NCT01165021 Background | Nov 2010 → Jul 2013 | non-small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT01116141 Background | Sep 2010 → Apr 2012 | rheumatoid arthritis | Chelsea Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01183065 Background | Aug 2010 → Apr 2014 | head and neck cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01010581 Background | Nov 2009 → Apr 2011 | rheumatoid arthritis | 4SC AG | Completed | No outcome recorded |
| Phase 2 | NCT01194453 Background | Nov 2009 → Sep 2010 | non-small cell lung carcinoma | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 2 | NCT01490437 Background | Jul 2008 → Dec 2013 | urothelial carcinoma | Asan Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00406874 Background | Jan → Dec 2007 | male infertility | Reproductive Partners Medical Group | Terminated | No outcome recorded |
| Phase 2 | NCT00693589 Comparator | Jan 2005 → Feb 2007 | cardiovascular disorder | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase 2 | NCT02093026 Background | Aug 2002 → Dec 2012 | rheumatoid arthritis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2/37 trials | ||||||
| Phase 2/3 | NCT07323329 Background | Oct 2025 → Oct 2026 expected | infertility disorder | Beni-Suef University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05096663 Background | Mar 2022 → Jun 2027 expected | non-small cell lung carcinoma | SWOG Cancer Research Network | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04616872 Comparator | Oct 2020 → Oct 2022 | atherosclerosis, coronary artery disorder | University of Sao Paulo General Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT04301336 Background | Nov 2019 → Nov 2020 | sickle cell disease | Beni-Suef University | Completed | No outcome recorded |
| Phase 2/3 | NCT03516903 Comparator | Apr 2018 → Dec 2020 | myocardial infarction | University of Sao Paulo | Terminated | No outcome recorded |
| Phase 2/3 | NCT01061736 Background | Mar 2010 → Oct 2013 | rheumatoid arthritis | Sanofi | Completed | No outcome recorded |
| Phase 2/3 | NCT00759811 Background | Dec 2007 → Nov 2008 | heart failure, myocardial ischemia | Instituto de Cardiologia do Rio Grande do Sul | Completed | No outcome recorded |
| Phase 324 trials | ||||||
| Phase 3 | NCT07630779 Background | Mar → Sep 2026 expected | polycystic ovary syndrome | Beni-Suef University | Recruiting | No outcome recorded |
| Phase 3 | NCT06965244 Comparator | Oct 2025 → Feb 2029 expected | cutaneous lupus erythematosus | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06405204 Comparator | Jun → Dec 2024 | — | Beni-Suef University | Unknown | No outcome recorded |
| Phase 3 | NCT06936215 Comparator | Jan 2024 → May 2025 overdue | diffuse cutaneous systemic sclerosis | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Recruiting | No outcome recorded |
| Phase 3 | NCT05590260 Comparator | May 2023 → Mar 2025 | — | NICHD Global Network for Women's and Children's Health | Completed | No outcome recorded |
| Phase 3 | NCT06059989 Background | Nov 2021 → Jun 2025 overdue | Crohn disease, inflammatory disease | Academic Medical Center - University of Amsterdam | Recruiting | No outcome recorded |
| Phase 3 | NCT04189367 Background | Jun 2020 → Jul 2022 | burning mouth syndrome | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04085354 Comparator | Feb → Jun 2019 | premature ejaculation | Sohag University | Completed | No outcome recorded |
| Phase 3 | NCT03750669 Background | Oct 2018 → Nov 2024 | pancreatic adenocarcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Completed | No outcome recorded |
| Phase 3 | NCT03120949 Background | Jul 2017 → Sep 2021 | rheumatoid arthritis | R-Pharm International, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02759120 Background | Mar 2017 → Mar 2020 | idiopathic pulmonary fibrosis | Weill Medical College of Cornell University | Terminated | No outcome recorded |
| Phase 3 | NCT03193788 Background | Jan 2017 → Dec 2019 | transitional cell carcinoma, ureter cancer, urinary bladder cancer | Asan Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT02930343 Comparator | Sep 2016 → Aug 2018 | rheumatoid arthritis | Jawaharlal Institute of Postgraduate Medical Education & Research | Terminated | No outcome recorded |
| Phase 3 | NCT02762838 Background | Jan 2016 → Jul 2018 | rheumatoid arthritis | Biocad | Completed | No outcome recorded |
| Phase 3 | NCT03172325 Background | Nov 2015 → Aug 2016 | rheumatoid arthritis | Cinnagen | Completed | No outcome recorded |
| Phase 3 | NCT02541708 Comparator | Sep 2015 → Apr 2018 | iron deficiency anemia | Ifakara Health Institute | Unknown | No outcome recorded |
| Phase 3 | NCT02293902 Background | Nov 2014 → Oct 2016 | rheumatoid arthritis | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01711359 Background | Nov 2012 → Feb 2015 | rheumatoid arthritis | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT01244347 Comparator | Jul 2009 → Sep 2015 | developmental defect during embryogenesis | Azienda Ospedaliera Universitaria Integrata Verona | Unknown | No outcome recorded |
| Phase 3 | NCT00806819 Comparator | Dec 2008 → Jun 2011 | non-small cell lung carcinoma | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT00578305 Background | Nov 2007 → Nov 2009 | rheumatoid arthritis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00397917 Comparator | Nov 2006 → May 2012 | cleft lip, cleft palate | University of Iowa | Completed | No outcome recorded |
| Phase 3 | NCT00354081 Comparator | Apr 1999 → Jun 2007 | coronary artery disorder, myocardial infarction, stroke disorder | Haukeland University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00470522 Background | Jun 1995 → Dec 2001 | systemic lupus erythematosus | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 424 trials | ||||||
| Phase 4 | NCT06015750 Background | Jul 2026 → Mar 2030 | hypophosphatasia | Alexion Pharmaceuticals, Inc. | Withdrawn | No outcome recorded |
| Phase 4 | NCT06943482 Background | Jul 2025 → Feb 2028 expected | granulomatous mastitis | National University Hospital, Singapore | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07701525 Comparator | Jun → Nov 2025 | polycystic ovary syndrome | Nishtar Medical University | Completed | No outcome recorded |
| Phase 4 | NCT06610266 Comparator | Feb 2025 → Oct 2026 expected | gastric intestinal metaplasia | Yongquan Shi | Recruiting | No outcome recorded |
| Phase 4 | NCT05169021 Comparator | Dec 2021 → Dec 2024 overdue | stroke disorder | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04579848 Comparator | Aug 2021 → Dec 2026 expected | arthropathy, erosive, osteoarthritis, hand | Diakonhjemmet Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03994731 Background | Jun 2019 → Mar 2021 | gout | Amgen | Completed | No outcome recorded |
| Phase 4 | NCT03635957 Background | Sep 2018 → Oct 2019 | gout | Amgen | Completed | No outcome recorded |
| Phase 4 | NCT03472508 Comparator | Mar 2018 → Mar 2019 | hypertensive disorder | Shenzhen Ausa Pharmed Co.,Ltd | Unknown | No outcome recorded |
| Phase 4 | NCT03040219 Comparator | Apr → Nov 2017 | protein-energy malnutrition | Ain Shams University | Unknown | No outcome recorded |
| Phase 4 | NCT03010579 Comparator | Oct 2016 → Dec 2017 | anemia, lymphoma | Peking University | Unknown | No outcome recorded |
| Phase 4 | NCT02644499 Comparator | Dec 2015 → Feb 2017 | rheumatoid arthritis | Jawaharlal Institute of Postgraduate Medical Education & Research | Completed | No outcome recorded |
| Phase 4 | NCT02817503 Background | Dec 2015 → Dec 2016 | hyperhomocysteinemia, hypertensive disorder | Second Affiliated Hospital of Nanchang University | Unknown | No outcome recorded |
| Phase 4 | NCT02444013 Comparator | May 2015 → May 2017 | kidney disorder | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 4 | NCT02031289 Comparator | Dec 2013 → Dec 2017 | anemia, disorder of iron metabolism and transport | University of Zurich | Completed | No outcome recorded |
| Phase 4 | NCT01921192 Comparator | Sep 2012 → Jul 2014 | proliferative diabetic retinopathy | University of Catania | Unknown | No outcome recorded |
| Phase 4 | NCT01583959 Comparator | Apr 2012 → Nov 2013 | rheumatoid arthritis | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 4 | NCT01315990 Background | Jan 2011 → Mar 2015 | colorectal cancer | Dr. Carl Schimanski | Unknown | No outcome recorded |
| Phase 4 | NCT01263080 Comparator | Nov 2010 → Dec 2012 | schizophrenia | Capital Medical University | Completed | No outcome recorded |
| Phase 4 | NCT02620345 Background | Jan 2010 → Oct 2015 | benign neoplasm of corpus uteri | Trieu, Nguyen Thi, M.D. | Completed | No outcome recorded |
| Phase 4 | NCT01608347 Comparator | Jan 2010 → Sep 2012 | pregnancy loss, recurrent, 4 | Omar Mamdouh Shaaban | Completed | No outcome recorded |
| Phase 4 | NCT00522821 Background | Nov 2007 → Jul 2014 | infectious disease, selective IgG subclass deficiency | Prothya Biosolutions | Completed | No outcome recorded |
| Phase 4 | NCT01514942 Background | — | polycystic ovary syndrome | AGUNCO Obstetrics and Gynecology Centre | Completed | No outcome recorded |
| Phase 4 | NCT01511835 Comparator | — | gestational diabetes | AGUNCO Obstetrics and Gynecology Centre | Unknown | No outcome recorded |
| Phase not applicable14 trials | ||||||
| — | NCT06875947 Background | May 2025 → Apr 2026 overdue | iron deficiency anemia, pregnancy disorder | Padjadjaran University | Active not recruiting | No outcome recorded |
| — | NCT06847139 Comparator | Jul 2024 → Jul 2025 overdue | chronic kidney disease | Chittagong Medical College | Recruiting | No outcome recorded |
| — | NCT05943158 Background | Jun 2021 → Jun 2022 | pregnancy disorder | Near East University, Turkey | Completed | No outcome recorded |
| — | NCT04892186 Background | Mar 2021 → Oct 2023 | glucose intolerance, polycystic ovary syndrome | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| — | NCT04755322 Background | Mar 2021 → Jul 2023 | preeclampsia | Assiut University | Completed | No outcome recorded |
| — | NCT04664010 Background | Feb 2020 → Sep 2022 | COVID-19 | Xi'an International Medical Center Hospital | Completed | No outcome recorded |
| — | NCT04228263 Background | Jan 2020 → Mar 2023 | pregnancy loss, recurrent, 4 | Assiut University | Completed | No outcome recorded |
| — | NCT03293641 Background | May 2016 → Jan 2017 | disorder of zinc metabolism, infectious disease, sickle cell disease | Lucas Otieno Tina, MD MSc | Completed | No outcome recorded |
| — | NCT01555190 Comparator | Jan 2012 → Dec 2013 | hypertrichosis, menstrual disorder, polycystic ovary syndrome | Catholic University of the Sacred Heart | Completed | No outcome recorded |
| — | NCT00459264 Comparator | Dec 2005 → Jun 2011 | bipolar disorder, depressive disorder | University of Oxford | Completed | No outcome recorded |
| — | NCT01095211 Comparator | Jan 2003 → Sep 2005 | cognitive disorder | Saarland University | Completed | No outcome recorded |
| — | NCT00269542 Background | Feb 2002 → Mar 2003 | diarrheal disease, pneumonia | Society for Applied Studies | Completed | No outcome recorded |
| — | NCT00097669 Comparator | Nov 1998 → Jun 2009 | transient ischemic attack | VITATOPS | Completed | No outcome recorded |
| — | NCT00626223 Comparator | Jan 1998 → Jul 2001 | hyperhomocysteinemia | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-10-18 | Takeda | Shire Granted EU Marketing Authorization of ONIVYDE®, In Combination With 5-Fluorouracil (5-FU) And Leucovorin (LV), For The Treatment of Metastatic Adenocarcinoma Of The Pancreas in Adult Patients Who Have Progressed Following Gemcitabine-Based Therapy takeda.com ↗ |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 218 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Folic Acid | “The experimental group received one tablet of Tenavit® (pyridoxine hydrochloride 4.00mg + folic acid 0.80mg + cyanocobalamin 0.40mg) daily and the placebo group received the...” NCT03221816 ↗216“Vitamin B-9 capsule Manufacturer: Hebei Jiheng pharmaceutical Co. Ltd generic name: folic acid. Constituent components: 5 mg of folic acid. Route of administration: orally...” NCT05435378 ↗ “food supplement containing 2000 mg L-carnitine, 2000 mg fructose, 932 mg acetyl L-carnitine, 225 mg vitamin C, 115 mg citric acid, 50 mg coenzyme Q10, 14 mg zinc, 115 µg...” NCT06042738 ↗ “Specifically for this study, the methyl donor supplement has been made by Jamieson Laboratories, and consists of 50mg Vitamin B6 and 1 mg Vitamin B12, (both within Health...” NCT01864824 ↗ “This group is given myoinositol+d-chiro inositol+folic acid once a day (inofolic combi, ITF company, Italy) (myoinositol 550 miligram+ d-chiroinositol 13,8 miligram+folic acid...” NCT05951309 ↗ “Participants will receive an oral combination tablet containing myo-inositol (550 mg), D-chiro-inositol (13.8 mg) in a 40:1 ratio, and folic acid (200 µg), taken twice daily...” NCT07701525 ↗ “Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU,...” NCT02421887 ↗ “myo-inositol 600µgm + folic acid 0.2 mg) 2 capsules at the morning and 2 capsules at the evening on empty stomach for 12 weeks produced by a Lo.Li pharma international ,Rome.Italy .” NCT05900661 ↗ “Participants received a daily capsule containing 40 mg of folic acid, 100 mg of pyridoxine hydrochloride (vitamin B6), and 2 mg of cyanocobalamin (vitamin B12) or a placebo.” PMID 17848650 ↗ Sep 2007 “Patients were treated with a 6-month course of metformin (1,700 mg daily) plus folic acid (400 microg daily; experimental group, n = 25) or placebo (control group, n = 25).” PMID 19933994 ↗ Nov 2009 “different dietary agents were used in the past for the treatment of elevated total plasma homocysteine (T-HCy), e. g. betaine, choline (betaine precursor) or folic acid.” NCT01371357 ↗ “Patients receiving conventional treatment to heart failure who will receive methotrexate 7.5mg oral plus folic acid 5mg oral once a week for 12 weeks.” NCT00759811 ↗ “Antimicrobials included co-trimoxazole (trimethoprim 160 mg/sulfamethoxazole 800 mg twice daily plus folic acid 5 mg daily, n = 128) or doxycycline” PMID 33974018 ↗ May 2021 “For the purpose of this study only 1 mg folic acid (corresponding to 0.2 mL Folarell®) will be injected 5 min prior to \[18F\]-AzaFol.” NCT03242993 ↗ “Nutritional supplement: vitamin B12, folic acid, iron, zinc, vitamin B complex depending on the hematic deficiency, for 12 weeks” NCT04189367 ↗ “Single capsule with 80mg low-dose aspirin, 1.2 grams calcium, 600 IU vitamin D, 5mg folic acid and 1000 ug vitamin B12 mixed.” NCT02007837 ↗ “The combined use of enalapril and folic acid, compared with enalapril alone, significantly reduced the risk of first stroke.” NCT02817503 ↗ “Throughout the study, concomitant treatment with folic acid ≥ 5 mg per week or equivalent was required for all subjects.” NCT03120949 ↗ “The vitamin intervention was a daily oral dose of one tablet consisting of folic acid 400 mcg + vitamin B12 100 mcg.” NCT00214682 ↗ “Folic acid 400mg/m\^2, 5- fluorouracil 2400mg/m\^2 for 46h, irinotecan 135mg/m\^2 and oxaliplatin 68mg/m\^2” NCT03750669 ↗ “The multivitamin for the intervention group has 5 ing folic acid, 1.7 mg B2, 100 mg B6, and I mg B12.” NCT00018460 ↗ “Group II (experiment) - they will receive myo-inositol 2g + folic acid 200mcg, orally, twice a day.” NCT04892186 ↗ “methotrexate 15 mg/week sc. in combination with oral folic acid 5mg/week will be prescribed.” NCT06059989 ↗ “Folic acid 350 ug - 600 ug daily from D-7 daily vitamin B12 1,000 ug every 9 weeks from D-7” NCT01490437 ↗ “Epigallocatechin gallate 200mg, Hyaluronic acid 50mg, Vitamin B12 1mg, Folic acid 400mcg” NCT06098456 ↗ “In the routine group, women received 60 mg ferrous sulfate plus 400 μg folic acid daily.” PMID 27297013 ↗ Jun 2016 “If necessary, oral ferrous succinate, vitamins B12 and folic acid will be administered.” NCT03010579 ↗ “along with an equal dose of folic acid supplementation given 48 hours after each dose” NCT06965244 ↗ “intravenous folic acid 200 mg/m2 intravenous OXA 85 mg/m² intravenous TXT 50 mg/m²” NCT06459921 ↗ “Pyridoxine Hydrochloride 2.6 mg/day Folic Acid 400 mcg/day Cyanocobalamin 4mcg/day” NCT02620345 ↗ “receive either oral folic acid 10 mg three times a week on post dialysis sessions” NCT00317005 ↗ “Folic acid (Leucovorin) 400mg/m2 (D,L, racemic form) or 200mg/m2 (L-isomer form)” NCT07284277 ↗ “5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.” NCT01857310 ↗ “5 mg Folic acid, plus 1 mg cyanocobalamin and 40 mg vitamin B6) oral/ day.” NCT01095211 ↗ “5mg amlodipine combined with 0.4mg folic acid,once daily (Low-dose group)” NCT01956786 ↗ “100 microgram(mcg folic acid, and 50 mcg cyanocobalamin (B12) and biotin” NCT01474486 ↗ “Folic acid: 5-10mg/week, oral administration, a total of 30 doses” NCT04178850 ↗ “Folic Acid, Proguanil, Penicillin V, Hydroxyurea over 6 months” NCT03293641 ↗ “All patients will receive Folic acid 2 to 5 mg once daily.” NCT07292259 ↗ “different levels of folic acid, Vitamin B12, iron and zinc” NCT00394862 ↗ “Patients take vitamin E capsule and folic acid every day.” NCT04664010 ↗ “5mg amlodipine combined with 0.4 mg of folic acid, daily.” NCT01848873 ↗ “participants are also required to take folic acid” NCT03994731 ↗ “minimum of 1 mg folic acid taken orally every day” NCT05363917 ↗ “FOLFIRI includes folic acid, 5-FU and irinotecan.” NCT06855849 ↗ “Folic acid (racemic) 400 mg/m², 120 min on day 1” NCT01315990 ↗ “Folic acid 5mg by mouth (the day after MTX-LDE)” NCT04616872 ↗ “Folic Acid Folic Acid 5 mg po once daily” NCT04813471 ↗ “Dietary Supplement: Folic Acid” NCT07630779 ↗ “Dietary Supplement: Folic Acid” NCT03635957 ↗ “combined with 5 mg folic acid” NCT00522821 ↗ “Folic acid 400mg/m\^2” NCT03977272 ↗ “5 mg daily folic acid” NCT01704599 ↗ “Folic acid: 5.0 mg” NCT00064753 ↗ “Folic Acid” NCT05096663 ↗ |
| Known as | acidum folicum | “Folic acid (Acidum folicum, Streuli Pharma AG, Uznach) 5 mg po.” NCT02031289 ↗1“5 mg oral folic acid (acidum folicum)” NCT04343170 ↗ |
| Known as | Colicid | “Folic acid will be used in the intervention stage in 5 mg tablets, box with 20 tablets, under the trade name Colicid from Bruluagsa.” NCT05712044 ↗ |
| Known as | Folarell | “For the purpose of this study only 1 mg folic acid (corresponding to 0.2 mL Folarell®) will be injected 5 min prior to \[18F\]-AzaFol.” NCT03242993 ↗ |
| Known as | folate | “Throughout the study, participants received methylprednisolone 100 mg iv prior to infusion of the investigational drug, methotrexate 7.5 to 25 mg/week orally or parenterally,...” NCT00578305 ↗3“Two micronutrients fundamental to the process of spermatogenesis, folic acid (folate) and zinc, are of particular interest for fertility as they are of low cost and wide availability.” NCT01857310 ↗ “Acid folic (folate) 1mg to be administered once daily during the treatment period.” NCT02795299 ↗ “Drug: Folate (400mcg) and Vitamin B12 (100 mcg)” NCT00214682 ↗ |
| Known as | Folic Acid Supplementation | “Drug: Folic Acid Supplementation” NCT04301336 ↗ |
| Known as | Folic acid(R) | “Folic acid(R) 0.5mg tablets once daily for 3 months preconceptionally” NCT03766594 ↗ |
| Known as | Folina | “treated with 5 mg per day of oral folic acid (Folina® Schwarz Pharma, Milan, Italy).” NCT00626223 ↗ |
| Known as | GB242 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04178850 ↗ |
| Known as | Leucovorin | “Folic acid (Leucovorin) 400mg/m2 (D,L, racemic form) or 200mg/m2 (L-isomer form)” NCT07284277 ↗ |
| Known as | Vitamin B9 | “(Ferrofol capsules, Eipico, Egypt): Dried ferrous sulphate 150 mg + Folic acid (Vitamin B9) 150 mg at least 1 hour before or 2 hours after meals three times a day for 4 weeks.” NCT03481790 ↗ |
| Action | Inhibit | “Anti-TNF-alpha antibodies” NCT04178850 ↗ |
| Modality | Other / unclassified | “an adjunctive B-vitamin supplement” PMID 30771856 ↗ Jan 2019 |
| Route | Oral | “oral administration of folic acid 5mg /d for 4 weeks” NCT00136188 ↗ |